Encompass Health Corporation $EHC Shares Purchased by Sei Investments Co.

Sei Investments Co. boosted its position in Encompass Health Corporation (NYSE:EHC) by 34.9% in the 1st quarter, Holdings Channel reports. The fund owned 508,940 shares of the company’s stock after purchasing an additional 131,536 shares during the period. Sei Investments Co.’s holdings in Encompass Health were worth $49,228,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the business. EP Wealth Advisors LLC boosted its holdings in shares of Encompass Health by 2.4% during the second quarter. EP Wealth Advisors LLC now owns 3,694 shares of the company’s stock worth $453,000 after purchasing an additional 88 shares during the last quarter. Allworth Financial LP grew its position in shares of Encompass Health by 14.7% in the third quarter. Allworth Financial LP now owns 701 shares of the company’s stock valued at $89,000 after purchasing an additional 90 shares during the period. Gibson Capital LLC increased its stake in Encompass Health by 4.3% in the first quarter. Gibson Capital LLC now owns 2,431 shares of the company’s stock valued at $235,000 after purchasing an additional 101 shares during the last quarter. Leuthold Group LLC lifted its position in Encompass Health by 0.3% during the fourth quarter. Leuthold Group LLC now owns 31,168 shares of the company’s stock worth $3,308,000 after buying an additional 104 shares during the period. Finally, Covestor Ltd boosted its stake in Encompass Health by 24.4% in the 4th quarter. Covestor Ltd now owns 540 shares of the company’s stock worth $57,000 after buying an additional 106 shares during the last quarter. Hedge funds and other institutional investors own 97.25% of the company’s stock.

Encompass Health Stock Performance

Shares of NYSE:EHC opened at $112.66 on Friday. The firm has a market capitalization of $11.18 billion, a PE ratio of 18.81, a P/E/G ratio of 2.46 and a beta of 0.74. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.17 and a quick ratio of 1.17. The business has a 50-day moving average of $104.97 and a two-hundred day moving average of $103.80. Encompass Health Corporation has a 12 month low of $92.77 and a 12 month high of $127.99.

Encompass Health (NYSE:EHC) last released its quarterly earnings data on Thursday, April 30th. The company reported $1.60 EPS for the quarter, topping analysts’ consensus estimates of $1.51 by $0.09. Encompass Health had a return on equity of 18.28% and a net margin of 10.04%.The company had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.57 billion. During the same period last year, the business posted $1.37 EPS. The company’s quarterly revenue was up 9.0% compared to the same quarter last year. Encompass Health has set its FY 2026 guidance at 5.890-6.110 EPS. As a group, research analysts forecast that Encompass Health Corporation will post 5.96 earnings per share for the current year.

Encompass Health Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Thursday, October 1st will be paid a $0.21 dividend. The ex-dividend date of this dividend is Thursday, October 1st. This represents a $0.84 dividend on an annualized basis and a dividend yield of 0.7%. This is a boost from Encompass Health’s previous quarterly dividend of $0.19. Encompass Health’s payout ratio is 12.69%.

Insider Transactions at Encompass Health

In related news, EVP Patrick William Tuer sold 682 shares of the stock in a transaction on Monday, May 11th. The stock was sold at an average price of $104.56, for a total value of $71,309.92. Following the completion of the sale, the executive vice president directly owned 24,755 shares in the company, valued at approximately $2,588,382.80. This represents a 2.68% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 1.80% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on EHC. Barclays lowered their price target on Encompass Health from $153.00 to $140.00 and set an “overweight” rating for the company in a report on Tuesday, May 5th. Leerink Partners set a $152.00 target price on shares of Encompass Health in a research report on Friday, May 22nd. TD Cowen assumed coverage on shares of Encompass Health in a report on Thursday, May 28th. They issued a “buy” rating and a $125.00 target price for the company. Wall Street Zen raised shares of Encompass Health from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Finally, Weiss Ratings downgraded shares of Encompass Health from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, June 26th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Encompass Health currently has a consensus rating of “Moderate Buy” and an average target price of $143.86.

About Encompass Health

Encompass Health Corporation is a leading provider of post?acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end?of?life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.